Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by CanadaCoinon Oct 27, 2019 4:38pm
104 Views
Post# 30274582

RE:RE:RE:The Parade!

RE:RE:RE:The Parade!
HailMary wrote:

One area that we will disagree on I'm sure.  I am not confident that the drug ever gets to market.  Odds are stacked against ATE, with only 1/5000 new drugs ever getting that far.   Phase 3 will involve 2000-3000 participants, will take upwards of 2-3 years to complete, and is going to cost a lot of money.  Most of that many will be raised off the backs of current shareholders thru more dilution, and with any luck, some assistance from a future partner.



Well, at least you know how 'high risk' BioTech/Pharma investing works. If it's not for you, then fine. But we still won't accpet your data without you disclosing the source of such information. For you see, this is also another piece of wise investing, figuring out where to place credibility. Right now you still have zero. Because of your stubbornness. :) 

And before you try and turn this against me, let me state that I have not presented any questionable stats/data that requires me to reveal a source of my posting. Therefore, my credibility has not come into play. And when I do post factual information or data.....I always include a link, document, quote, to prove my source. 
Bullboard Posts